Cargando…
Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of the survival motor neuron (SMN) gene. While there are currently two approved gene-based therapies for SMA, availability, high cost, and differences in patient response indicate that alternative treatment options are needed. O...
Autores principales: | Ahlskog, Nina, Hayler, Daniel, Krueger, Anja, Kubinski, Sabrina, Claus, Peter, Hammond, Suzan M., Wood, Matthew J. A., Yáñez-Muñoz, Rafael J., Bowerman, Melissa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674152/ https://www.ncbi.nlm.nih.gov/pubmed/32313099 http://dx.doi.org/10.1038/s41434-020-0146-8 |
Ejemplares similares
-
Dysregulation of Tweak and Fn14 in skeletal muscle of spinal muscular atrophy mice
por: Meijboom, Katharina E., et al.
Publicado: (2022) -
Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2021) -
The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020) -
Therapeutic strategies for spinal muscular atrophy: SMN and beyond
por: Bowerman, Melissa, et al.
Publicado: (2017) -
Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy
por: Hammond, Suzan M., et al.
Publicado: (2022)